Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a transformative fourth quarter, with a key regulatory milestone and important data readouts expected by year-end.
The company has one marketed drug, Korlym, used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or cannot have surgery. The drug, which received FDA approval in February 2012, has experienced significant revenue growth since its launch, increasing from $3.31 million in 2012 to $482.4 million in 2023.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.